Nectar Lifesciences Ltd. has successfully completed a slump sale and asset sale valued at ₹1,253.99 crore on November 10, 2025. This transaction follows a business transfer agreement (BTA) and an asset purchase agreement (APA) both executed on July 7, 2025, between Nectar Lifesciences and Ceph Lifesciences Private Limited. The completion of this sale is a significant milestone for the company, which has been working to streamline its operations and focus on core business areas.

The financial outcome of the slump sale is driven by working capital adjustments as outlined in the BTA, amounting to ₹1,253.99 crore. Meanwhile, the asset purchase agreement remains unchanged at ₹20 crore, as disclosed previously. This strategic move not only enhances Nectar Lifesciences' financial standing but also signals its commitment to optimizing its asset portfolio for better operational efficiency.

The announcement was made through a regulatory filing, adhering to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The stock exchange notification emphasized the importance of this transaction for both companies involved, further solidifying Nectar Lifesciences' position in the competitive pharmaceutical landscape. As the company moves forward, stakeholders are keenly observing how this transition will impact its future growth trajectory.